IDEAYA Biosciences, Inc. (IDYA) Q4 2020 Earnings Results

IDEAYA Biosciences I Beats on EPS, Stock Down 1.6%

IDEAYA Biosciences reported a narrower-than-expected loss per share, which is a positive sign for investors. However, the stock still fell by 1.6% in reaction to the earnings report. The lack of revenue data and forward guidance may have contributed to the stock's decline, as investors often look for clearer future expectations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.18	N/A	+2.17%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the advancements made in their pipeline. They emphasized their commitment to executing strategic initiatives.

We are pleased with our progress in advancing our pipeline.

Our focus remains on executing our strategic initiatives.

IDEAYA Biosciences I Beats on EPS, Stock Down 1.6%

Key numbers

Management commentary

IDEAYA Biosciences, Inc.

More earnings this week

IDEAYA Biosciences I Beats on EPS, Stock Down 1.6%

Key numbers

Management commentary